Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)

<Previous Article In Volume
Next Article In Volume>

Survival Rate of Patients with Diffuse Large B-Cell Lymphoma in the Head and Neck

Authors
Yussy Afriani Dewi1, *, Agung Dinasti Permana1, Ifiq Budiyan Nazar1, Bethy Suryawathy Hernowo2
1Division of Oncology Head and Neck Surgery, Department of Otorhinolaryngology, Faculty of Medicine Universitas Padjadjaran/Hasan Sadikin Hospital Bandung West Java, Indonesia
2Department of Anatomic Pathology, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia
*Corresponding author. Email: yussy.afriani@unpad.ac.id
Corresponding Author
Yussy Afriani Dewi
Available Online 21 February 2022.
DOI
10.2991/ahsr.k.220206.015How to use a DOI?
Keywords
Cancer antigen 125; Diffuse large B-cell lymphoma; Head and Neck; Lactate dehydrogenase; Survival rate
Abstract

Diffuse large B-cell lymphoma (DLBCL) is a subtype of aggressive non-Hodgkin lymphoma (NHL). Diffuse Large B-cell lymphoma is a subtype of lymphoma most often found in the head and neck region. Overall survival could be used in assessing the effectiveness of therapies that may affect prognosis and survival. This study aimed to determine the survival rate of patients with DLBCL in the head and neck. This study used a retrospective cohort design, data was taken from the cancer registry between January 2014 and December 2019 at Hasan Sadikin Hospital Bandung and traced the history of survival. The analysis was using Kaplan-meier and all data were analyzed using Statistical Package for the Social Sciences (SPSS) application. The results showed that 148 patients with DLBCL obtained 76 patients (51.4%) male and 72 patients (48.6%) female. About 79 patients (53.4%) were Stage I, 108 patients (73%) ECOG 0. The mean lactate dehydrogenase (LDH) level was 253.76 and 32.48 U/mL Cancer antigen 125 (Ca-125). The 130 patients (87.8%) underwent chemotherapy and 18 (12.2%) chemoradiation. Median survival in DLBCL were 3 year (2.448-3.552, 95% CI). as many as 50% of subjects had died within 3 years. Age, education, stage, ECOG, LDH, IPI, Ca-125, and comorbid had a significant effect in 3-years survival rate of DLBCL patients.

Copyright
© 2022 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
Series
Advances in Health Sciences Research
Publication Date
21 February 2022
ISBN
10.2991/ahsr.k.220206.015
ISSN
2468-5739
DOI
10.2991/ahsr.k.220206.015How to use a DOI?
Copyright
© 2022 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Cite this article

risenwbib
TY  - CONF
AU  - Yussy Afriani Dewi
AU  - Agung Dinasti Permana
AU  - Ifiq Budiyan Nazar
AU  - Bethy Suryawathy Hernowo
PY  - 2022
DA  - 2022/02/21
TI  - Survival Rate of Patients with Diffuse Large B-Cell Lymphoma in the Head and Neck
BT  - Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
PB  - Atlantis Press
SP  - 71
EP  - 77
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.220206.015
DO  - 10.2991/ahsr.k.220206.015
ID  - Dewi2022
ER  -